Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;12(3):741-752.
doi: 10.1007/s13555-022-00691-4. Epub 2022 Feb 24.

Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database

Timothy Fitzgerald  1 , Aimee M Near  2 , Hyunchung Kim  3 , Amanda Teeple  1 , Mobolaji Olurinde  1 , Katelyn Rowland  1
Affiliations

Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database

Timothy Fitzgerald et al. Dermatol Ther (Heidelb). 2022 Mar.

Abstract

Introduction: Biologics have expanded the treatment options in the management of patients with moderate-to-severe psoriasis. The objective of this study was to describe patient characteristics and previous treatments in psoriasis patients newly treated with guselkumab, secukinumab, or ixekizumab.

Methods: This retrospective study included patients ≥ 18 years old with psoriasis in the USA who were newly treated with guselkumab, secukinumab, or ixekizumab between 1 July 2017 and 31 March 2019 in the Modernizing Medicine Data Services database (MMDS). Patients were indexed on their first prescription or injection record of guselkumab, secukinumab, or ixekizumab, and three mutually exclusive cohorts were created. Patients were required to have evidence of moderate-to-severe psoriasis, defined as Physician Global Assessment (PGA) score of 3 or 4, or body surface area (BSA) ≥ 10% on index date or within 12 months before index. Baseline characteristics, including treatment history, were reported for each cohort.

Results: The study population included 461 guselkumab, 619 secukinumab, and 375 ixekizumab patients. The median age across cohorts was 51-52 years. Median baseline BSA ranged from 15% to 20%; 16.1-29.3% of patients had a PGA of 4 and over half of patients were obese prior to index. Approximately 40% of patients had comorbid cardiovascular disease and 20.8-24.2% of patients had a psychiatric disorder. About half of patients in each cohort had prior biologic use, of which adalimumab was most common (28.2-34.9%) across the cohorts.

Conclusion: This real-world study describes the characteristics of patients with moderate-to-severe psoriasis receiving biologic treatments.

Keywords: Biologics; Body surface area; Electronic medical record; Guselkumab; Ixekizumab; Modernizing medicine data services; Physician global assessment; Psoriasis; Real-world; Secukinumab.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient selection criteria and attrition of study cohorts
Fig. 2
Fig. 2
a Prior treatments of the patient population at baseline in study cohorts. b Prior use of biologics other than index treatment at baseline in study cohorts
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi: 10.1111/bjd.18245. - DOI - PMC - PubMed
    1. Strober BE, Germino R, Guana A, Greenberg JD, Litman HJ, Guo N, et al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J Dermatolog Treat. 2020;31(4):333–341. doi: 10.1080/09546634.2019.1603361. - DOI - PubMed
    1. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057. - DOI - PubMed
    1. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi: 10.3390/ijms20061475. - DOI - PMC - PubMed
    1. Aurangabadkar SJ. Comorbidities in psoriasis. Indian J Dermatol Venereol Leprol. 2013;79(Suppl 7):S10–S17. doi: 10.4103/0378-6323.115506. - DOI - PubMed

LinkOut - more resources